Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-20
    E.g., 2018-02-20

Articles

13798 items
4:39 PM, Jan 31, 2018  |  BC Innovations | Emerging Company Profile

Non-adherence policy

Having worked out how to make non-adherent primary cells amenable to microscopy, Allcyte GmbH has created a platform for imaging interactions between T cells and B cells that can predict drug responses in hematological cancers....
2:11 PM, Jan 31, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor survival....
2:10 PM, Jan 31, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Cell culture, patient sample and mouse studies identified a CAMP-based antibacterial peptide that could help treat multidrug-resistant (MDR) bacterial infections. Chemical synthesis and bacterial viability assays of CAMP analogs yielded a peptide that...
2:10 PM, Jan 31, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Parkinson's disease (PD) Patient samples and mouse studies suggest promoting clearance of CDKN2A-positive senescent cells could help treat PD. In postmortem substantia nigra tissue samples from patients, levels of the cellular senescence cell marker CDKN2A...
9:01 AM, Jan 31, 2018  |  BC Innovations | Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of RPS6KA5 could help predict survival in ESR1-positive breast cancer. In 193 patients, low primary tumor levels of RPS6KA5 mRNA were associated with poor metastasis-free survival. In another 214 patients, low...
9:01 AM, Jan 31, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies suggest combining CD40 agonists and CSF1R inhibitors could help treat colorectal cancer. In two mouse models of colon cancer, an anti-CD40 agonist antibody plus an anti-CSF1R antibody inhibitor decreased tumor...
4:53 PM, Jan 30, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Addiction Mouse studies suggest inhibiting G-CSF could help treat cocaine addiction. In a mouse conditioned place preference (CPP) model of cocaine reward, nucleus accumbens injection of an anti-G-CSF antibody decreased cocaine reward-seeking behavior compared with...
4:53 PM, Jan 30, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies identified a prodrug of a TrkB agonist that could help treat AD. Chemical synthesis and testing in mouse-based PK assays of prodrugs of a 7,8-dihydroxyflavone-based TrkB agonist yielded a carbamate-functionalized...
4:52 PM, Jan 30, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest inhibiting miR-143 or promoting expression of its inhibitor DLGAP4’s circular RNA (circRNA) could help treat stroke. In serum samples from patients, levels of miR-143 were higher and levels...
4:52 PM, Jan 30, 2018  |  BC Innovations | Distillery Techniques

Disease models

TECHNOLOGY: Animal models Somatic cell nuclear transfer (SCNT) could be used to clone macaques for use as genetically uniform disease models. The macaques are cloned via SCNT using fetal monkey fibroblasts or adult monkey cumulus cells,...

Pages